Vaccine-Preventable Diseases: Bacterial
CDC Yellow Book 2024
Travel-Associated Infections & DiseasesTable 5-01: Vaccine-Preventable Diseases: Bacterial
| VACCINE | TRADE NAME (MANUFACTURER) | DESCRIPTION1 & ROUTE OF ADMINISTRATION | AGE LIMITS | DOSES | PRESCRIBING & BOOSTER INFORMATION, RECOMMENDATIONS & RESTRICTIONS |
|---|---|---|---|---|---|
|
Anthrax |
BioThrax (Emergent BioSolutions) |
Cell-free filtrates of avirulent Bacillus anthracis, IM or SC (SC preferred) |
18–65 y |
3 |
|
|
Cholera |
VAXCHORA (Emergent BioSolutions) |
Live-attenuated, PO |
50 mL |
1 |
|
|
100 mL |
1 |
||||
|
Diphtheria |
For all diphtheria vaccines licensed for use in the United States, see: Vaccines Licensed for Use in the United States | ||||
|
Diphtheria |
Adacel (TDaP) (Sanofi Pasteur) |
Tetanus, diphtheria toxoids + acellular pertussis antigens, IM |
10–64 y |
1 |
|
|
Diphtheria |
BOOSTRIX (TDaP) (GlaxoSmithKline) |
Tetanus, diphtheria toxoids + pertussis antigens, IM |
≥10 y |
1 |
|
|
Diphtheria |
TDVAX (MassBiologics) |
Tetanus, diphtheria toxoids, IM |
≥7 y |
3 (primary series) + 1 (booster) |
|
|
Diphtheria |
TENIVAC (Td) (Sanofi Pasteur) |
Tetanus, diphtheria toxoids, IM |
≥7 y |
3 (primary series) + 1 (booster) |
|
|
Meningococcal (Quadrivalent, ACWY) |
Menactra (Sanofi Pasteur) |
Conjugate, IM |
9–23 mo |
2 |
|
|
≥2 y |
1 |
||||
|
Meningococcal (Quadrivalent, ACWY) |
MenQuadfi (Sanofi Pasteur) |
Conjugate, IM |
≥2 y |
1 |
|
|
Meningococcal (Quadrivalent, ACWY) |
MENVEO (GlaxoSmithKline) |
Conjugate, IM |
2 mo |
4 |
|
|
Meningococcal (Quadrivalent, ACWY) |
3–6 mo |
Depends on age at 1st vaccination |
|||
|
Meningococcal (Quadrivalent, ACWY) |
7–23 mo |
2 |
|||
|
Meningococcal (Quadrivalent, ACWY) |
≥2 y |
1 |
|||
|
Meningococcal (Monovalent, B) |
BEXSERO (GlaxoSmithKline) |
Recombinant, IM |
10–25 y |
2 |
|
|
Meningococcal (Monovalent, B) |
TRUMENBA (Pfizer) |
Recombinant, IM |
10–25 y |
2 |
|
| Pertussis | For all pertussis vaccines licensed for use in the United States, see: Vaccines Licensed for Use in the United States | ||||
|
Pertussis |
Adacel (TDaP) (Sanofi Pasteur) |
Tetanus, diphtheria toxoids + acellular pertussis antigens, IM |
10–64 y |
1 |
|
|
Pertussis |
BOOSTRIX (TDaP) (GlaxoSmithKline) |
Tetanus, diphtheria toxoids + pertussis antigens, IM |
≥10 y |
1 |
|
| Plague | Discontinued in 1999; newer vaccines in development, none commercially available or FDA-approved | ||||
|
Pneumococcal |
PREVNAR 13 (Wyeth) |
Conjugate, IM |
6 wk to <6 y |
4 |
|
|
Pneumococcal |
6 y to <18 y |
1 |
|||
|
Pneumococcal |
VAXNEUVANCE (Merck) |
Conjugate, IM |
≥18 y |
1 |
|
|
Pneumococcal |
PREVNAR 20 (Wyeth) |
Conjugate, IM |
≥18 y |
1 |
|
|
Pneumococcal |
PNEUMOVAX 23 (Merck) |
Polysaccharide, IM or SC |
≥50 y |
1 |
PNEUMOVAX 23 - Pneumococcal Vaccine, Polyvalent |
| Q fever | Available in Australia only | ||||
| Tetanus | For all tetanus vaccines licensed for use in the United States, see: Vaccines Licensed for Use in the United States | ||||
|
Tetanus |
Adacel (TDaP) (Sanofi Pasteur) |
Tetanus, diphtheria toxoids + acellular pertussis antigens, IM |
10–64 y |
1 |
|
|
Tetanus |
BOOSTRIX (TDaP) (GlaxoSmithKline) |
Tetanus, diphtheria toxoids + pertussis antigens, IM |
≥10 y |
1 |
|
|
Tetanus |
TDVAX (MassBiologics) |
Tetanus, diphtheria toxoids, IM |
≥7 y |
3 (primary series) + 1 (booster) |
|
|
Tetanus |
TENIVAC (Td) (Sanofi Pasteur) |
Tetanus, diphtheria toxoids, IM |
≥7 y |
3 (primary series) + 1 (booster) |
|
| Tuberculosis | bacillus Calmette-Guérin (BCG) is no longer commercially available in the United States | ||||
|
Typhoid fever |
Typhim Vi (Sanofi Pasteur) |
Polysaccharide, IM |
≥2 y |
1 |
|
|
Typhoid fever |
Vivotif (Emergent BioSolutions) |
Live-attenuated, PO |
≥6 y |
4 |
|
Abbreviations: IM, intramuscular; PO, orally; SC, subcutaneously
1For an overview and description of vaccine types, see: www.hhs.gov/immunization/basics/types/index.html